Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II

Lynda E Polgreen, Alicia Kunin-Batson, Kyle Rudser, Richard K Vehe, Jeanine J Utz, Chester B Whitley, Patricia Dickson, Lynda E Polgreen, Alicia Kunin-Batson, Kyle Rudser, Richard K Vehe, Jeanine J Utz, Chester B Whitley, Patricia Dickson

Abstract

Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnormalities leading to pain, stiffness, physical dysfunction, and short stature. Tumor necrosis factor - alpha (TNF-α) is elevated in individuals with MPS I and II and associated with pain and physical dysfunction. Therefore, we evaluated the safety and effects of the TNF-α inhibitor adalimumab in patients with MPS I and II in a 32-week, randomized, double blind, placebo-controlled, crossover study of adalimumab at a dose of 20 mg (weight 15-<30 kg) or 40 mg (weight ≥ 30 kg) administered subcutaneously every other week or saline placebo for 16 weeks. Participants were evaluated at baseline, week 16, and week 32 with the Children's Health Questionnaire - Parent Form 50 (CHQ-PF50), the Pediatric Pain Questionnaire (PPQ), range-of-motion (ROM) measurements, anthropometry, six-minute walk test (6MWT), hand dynamometer, and laboratory evaluations for safety. The primary outcome was safety and primary efficacy outcome was bodily pain (BP) measured by the CHQ-PF50. Two subjects, one with MPS I and one with MPS II, completed the study. Adalimumab was well tolerated and there were no serious adverse events. Standardized BP scores for age and gender were higher (i.e. less pain) at the end of the treatment versus placebo phase for both subjects. Subject #1 became unblinded during treatment due to skin erythema. Behavior measured by both CHQ-PF50 and parental report improved during treatment compared to placebo in both subjects. ROM improved by > 5° in seven of eight joints in Subject #1 and five of eight joints in Subject #2 (range 7.0° to 52.8°). There was no change in the PPQ, 6MWT, or hand dynamometer. Data from this small pilot study suggest that treatment with adalimumab is safe, tolerable, and may improve ROM, physical function, and possibly pain, in children with MPS I or II. However, additional clinical trials are needed before this therapy should be recommended as part of clinical care.

Keywords: Bone; Inflammation; Joint; Mucopolysaccharidosis.

Figures

Fig. 1
Fig. 1
Changes in pain (BP), physical function (PF), Physical Health Summary Score (PhS), and Psychosocial Health Summary Score (PsS) measured by the CHQ-PF50, during treatment versus placebo. Increase in score means an improvement for all scales except BP where increase in score = decrease in pain.

References

    1. E.B. Fung, J.A. Johnson, J. Madden, T. Kim, P. Harmatz, Bone density assessment in patients with mucopolysaccharidosis: a preliminary report from patients with MPS II and VI, J. Pediatr. Rehabil. Med. 3 (n.d.) 13–23.
    1. Polgreen L.E., Tolar J., Plog M., Himes J.H., Orchard P.J., Whitley C.B., Miller B.S., Petryk A. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1005–1011.
    1. E. Oussoren, M.M. Brands, G.J. Ruijter, A.T. der Ploeg, A.J. Reuser, Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options, Biochim. Biophys. Acta 1812 (n.d.) 1542–56.
    1. Weisstein J.S., Delgado E., Steinbach L.S., Hart K., Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J. Pediatr. Orthop. 2004;24:97–101.
    1. Link B., de Camargo Pinto L.L., Giugliani R., Wraith J.E., Guffon N., Eich E., Beck M. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop. Rev. Pavia. 2010;2
    1. Jones S.A., Parini R., Harmatz P., Giugliani R., Fang J., Mendelsohn N.J. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS) Mol. Genet. Metab. 2013;109:41–48.
    1. Monroy M.A., Ross F.P., Teitelbaum S.L., Sands M.S. Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease. Bone. 2002;30:352–359.
    1. Rimoin D.L., Silberberg R., Hollister D.W. Chondro-osseous pathology in the chondrodystrophies. Clin. Orthop. Relat. Res. 1976:137–152.
    1. Nuttall J.D., Brumfield L.K., Fazzalari N.L., Hopwood J.J., Byers S. Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif. Tissue Int. 1999;65:47–52.
    1. Russell C., Hendson G., Jevon G., Matlock T., Yu J., Aklujkar M., Ng K.Y., Clarke L.A. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin. Genet. 1998;53:349–361.
    1. Silveri C.P., Kaplan F.S., Fallon M.D., Bayever E., August C.S. Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin. Orthop. Relat. Res. 1991:305–311.
    1. Simonaro C.M., D'Angelo M., Haskins M.E., Schuchman E.H. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res. 2005;57:701–707.
    1. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. 2010;107:222–227.
    1. Simonaro C.M., Haskins M.E., Schuchman E.H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab. Investig. J. Tech. Methods Pathol. 2001;81:1319–1328.
    1. Eliyahu E., Wolfson T., Ge Y., Jepsen K.J., Schuchman E.H., Simonaro C.M. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One. 2011;6
    1. de Oliveira P.G., Baldo G., Mayer F.Q., Martinelli B., Meurer L., Giugliani R., Matte U., Xavier R.M. Characterization of joint disease in mucopolysaccharidosis type I mice. Int. J. Exp. Pathol. 2013;94:305–311.
    1. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 2008;172:112–122.
    1. Simonaro C.M. Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation. J. Pediatr. Rehabil. Med. 2010;3:85–88.
    1. Martin D.C., Atmuri V., Hemming R.J., Farley J., Mort J.S., Byers S., Hombach-Klonisch S., Csoka A.B., Stern R., Triggs-Raine B.L. A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis. Hum. Mol. Genet. 2008;17:1904–1915.
    1. Polgreen L.E., Vehe R.K., Rudser K., Kunin-Batson A., Utz J.J., Dickson P., Shapiro E., Whitley C.B. Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol. Genet. Metab. 2016;117:427–430.
    1. Bresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J. Rheumatol. 2002;65:39–43.
    1. Chatzidakis I., Mamalaki C. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr. Dir. Autoimmun. 2010;11:105–118.
    1. Tugwell P., Wells G., Strand V., Maetzel A., Bombardier C., Crawford B., Dorrier C., Thompson A. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000;43:506–514.
    1. Strand V., Singh J.A. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121–145.
    1. Kosinski M., Zhao S.Z., Dedhiya S., Osterhaus J.T., Ware J.E., Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478–1487.
    1. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Wendt S., Puga A.C., Puga A., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet. Med. Off. J. Am. Coll. Med. Genet. 2006;8:465–473. (doi:10.109701.gim.0000232477.37660.fb)
    1. Muenzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome) Mol. Genet. Metab. 2007;90:329–337.
    1. Okuyama T., Tanaka A., Suzuki Y., Ida H., Tanaka T., Cox G.F., Eto Y., Orii T. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II) Mol. Genet. Metab. 2010;99:18–25.
    1. Schmidt M., Breyer S., Löbel U., Yarar S., Stücker R., Ullrich K., Müller I., Muschol N. Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation. Orphanet J. Rare Dis. 2016;11
    1. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001;344:182–188.
    1. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., Okazaki S., Huff K., Cox G.F., Swiedler S.J., Kakkis E.D. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol. Genet. Metab. 2007;90:171–180.
    1. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229–240.
    1. den Broeder A., van de Putte L., Rau R., Schattenkirchner M., Van Riel P., Sander O., Binder C., Fenner H., Bankmann Y., Velagapudi R., Kempeni J., Kupper H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. 2002;29:2288–2298.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner